Biological characterization of pegylated interferons: a case study.
Xie
Lei
L
Schering Plough Research Institute, Union, NJ, USA.
Cullen
Constance
C
Bradshaw
Sheri
S
DeLorenzo
Marc
M
Grace
Michael J
MJ
D000998:Antiviral Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004268:DNA-Binding Proteins / Q000378:metabolism; D005786:Gene Expression Regulation / Q000235:genetics; D015395:Histocompatibility Antigens Class I / Q000276:immunology / Q000378:metabolism; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry* / Q000276:immunology / Q000494:pharmacology* / Q000633:toxicity; D007694:Killer Cells, Natural / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000494:pharmacology* / Q000633:toxicity; D021381:Protein Transport; D011994:Recombinant Proteins; D050794:STAT1 Transcription Factor; D015534:Trans-Activators / Q000378:metabolism
D000998:Antiviral Agents; D004268:DNA-Binding Proteins; D015395:Histocompatibility Antigens Class I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D015534:Trans-Activators; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a